Literature DB >> 32927324

Enhanced Recovery after Surgery in Elderly Gastric Cancer Patients Undergoing Laparoscopic Total Gastrectomy.

Shougen Cao1, Taohua Zheng2, Hao Wang3, Zhaojian Niu1, Dong Chen1, Jian Zhang1, Liang Lv1, Yanbing Zhou4.   

Abstract

BACKGROUND: The aim of this study was to evaluate the effects of the enhanced recovery after surgery (ERAS) program versus conventional perioperative care on the short-term postoperative outcomes among elderly patients with gastric cancer who are undergoing laparoscopic total gastrectomy.
METHODS: Elderly patients with gastric cancer (age ≥ 65 y) who are undergoing laparoscopic total gastrectomy were randomized to ERAS or conventional perioperative care groups. Short-term postoperative outcomes, including postoperative hospital stay, mortality, complications, readmission rate, and reoperation rate were compared between the two groups. In addition, blood samples were taken preoperatively (baseline) and on postoperative days 1, 3, and 5. Systemic human leukocyte antigen (HLA)-DR expression on monocytes and C-reactive protein (CRP) were analyzed.
RESULTS: Of the 171 eligible patients, 85 patients were assigned to receive ERAS program treatment (ERAS group) and 86 patients to receive conventional care (conventional group). The patients' characteristics were comparable. Postoperative hospital stay was shorter in the ERAS group than in the conventional group (11 [7-11] versus 13 [8-20] d, P < 0.001). Hospital mortality, overall morbidity, morbidity ≥ Clavien-Dindo (C-D) grade II, readmission rate, and reoperation rate did not show significant differences between the two groups. However, morbidity ≥ C-D grade IIIa was lower in the ERAS group than that in the conventional group (8.2% versus 18.6%, P = 0.047). The ERAS program shortened the number of days to postoperative first flatus, first defecation, semifluid diet, and soft bland diet. Moreover, the ERAS program increased the HLA-DR expression on monocytes and decreased the CRP levels on postoperative days 1, 3, and 5.
CONCLUSIONS: The ERAS program was feasible and effective for elderly patients with gastric cancer who are undergoing laparoscopic total gastrectomy. The benefits of ERAS were associated with improvement of impaired immune function and suppression of inflammatory reaction.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Elderly patients; Enhanced recovery after surgery; Gastric cancer; Laparoscopic total gastrectomy

Year:  2020        PMID: 32927324     DOI: 10.1016/j.jss.2020.07.037

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  5 in total

1.  Effects of enhanced recovery after surgery on robotic radical prostatectomy: a systematic review and meta-analysis.

Authors:  Jiahui Xing; Juan Wang; Guanghua Liu; Yujie Jia
Journal:  Gland Surg       Date:  2021-12

2.  Effect of Enhanced Recovery after Surgery with Integrated Traditional Chinese and Western Medicine on Postoperative Stress Response of Patients with Gastrointestinal Tumors.

Authors:  Haiping Zhao; Wenhui Sun
Journal:  Comput Math Methods Med       Date:  2022-07-08       Impact factor: 2.809

3.  Immunonutrition reduces complications rate and length of stay after laparoscopic total gastrectomy: a single unit retrospective study.

Authors:  Marzia Franceschilli; Leandro Siragusa; Valeria Usai; Sirvjo Dhimolea; Brunella Pirozzi; Simone Sibio; Sara Di Carlo
Journal:  Discov Oncol       Date:  2022-07-11

4.  Enhanced Recovery Care vs. Traditional Care in Laparoscopic Hepatectomy: A Systematic Review and Meta-Analysis.

Authors:  Xueyin Zhou; Xueyi Zhou; Jiasheng Cao; Jiahao Hu; Win Topatana; Shijie Li; Sarun Juengpanich; Ziyi Lu; Bin Zhang; Xu Feng; Jiliang Shen; Mingyu Chen
Journal:  Front Surg       Date:  2022-03-22

5.  Analysis on Influencing Factors of Knowledge-Based Attitude and Behavior Change of Cardiovascular Disease Nurses.

Authors:  Manmei Yang; Yongping Wu; Lihua Peng; Xuhuan Kuang
Journal:  J Healthc Eng       Date:  2022-04-16       Impact factor: 3.822

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.